Stockscreener 앱 받기
1.40
7.28%
-0.11
시간 외 거래:
1.42
0.02
+1.43%
전일 마감가:
$1.51
열려 있는:
$1.46
하루 거래량:
1.91M
Relative Volume:
0.61
시가총액:
$79.33M
수익:
-
순이익/손실:
$-82.44M
주가수익비율:
-0.7447
EPS:
-1.88
순현금흐름:
$-66.75M
1주 성능:
-13.04%
1개월 성능:
-22.65%
6개월 성능:
-62.67%
1년 성능:
-72.60%
1일 변동 폭
$1.36
$1.51
1주일 범위
$1.36
$1.59
52주 변동 폭
$1.36
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
명칭
Black Diamond Therapeutics Inc
전화
617-417-5868
주소
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
BDTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.40 | 79.33M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-31 | 개시 | Raymond James | Outperform |
| 2023-07-14 | 개시 | Piper Sandler | Overweight |
| 2023-06-30 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-03-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-03-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-01-07 | 개시 | Wedbush | Outperform |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | Canaccord Genuity | Buy |
| 2020-02-24 | 개시 | Cowen | Outperform |
| 2020-02-24 | 개시 | JP Morgan | Overweight |
| 2020-02-24 | 개시 | Jefferies | Buy |
모두보기
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Black Diamond stock hits 52-week low at $1.42 amid challenges - Investing.com India
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Bank of New York Mellon Corp Purchases 65,341 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics’ Global Licensing Deal with Servier - Global Legal Chronicle
BDTX stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier - Seeking Alpha
What is Wedbush’s Estimate for BDTX Q1 Earnings? - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 37,472 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Small Cap Stocks To Follow TodayMarch 19th - MarketBeat
BB Biotech AG Reduces Stake in Black Diamond Therapeutics Inc - GuruFocus
Black Diamond Therapeutic Stock Price, Quotes and Forecasts | NASDAQ:BDTX - Benzinga
Stock Traders Buy High Volume of Call Options on Black Diamond Therapeutics (NASDAQ:BDTX) - Defense World
Growth Stocks To Add to Your Watchlist – March 19th - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Earns “Outperform” Rating from Wedbush - Defense World
HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings - Defense World
Black Diamond Therapeutics sees $11.99m stock sale by BB Biotech AG - Investing.com
Growth Stocks To Add to Your WatchlistMarch 19th - MarketBeat
Black Diamond Gets The Gift Of Time In License Pact With Servier - insights.citeline.com
Servier and Black Diamond enter oncology licensing deal By Investing.com - Investing.com South Africa
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, a Targeted Oncology Therapy - Marketscreener.com
Sector Update: Health Care -March 19, 2025 at 03:43 pm EDT - Marketscreener.com
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High - NewsBreak: Local News & Alerts
This Biotech Is Finding Mid-Week Success Following Licensing Agreement Announcement - The Globe and Mail
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Yea - Asianet Newsable
Black Diamond Therapeutics surges on licensing deal - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million - Benzinga
Black Diamond Therapeutics (BDTX) Stock Jumps After Entering Licensing Deal - Stocks Telegraph
Black Diamond stock surges on licensing deal (BDTX:NASDAQ) - Seeking Alpha
Servier and Black Diamond collaborate on BDTX-4933 - The Pharma Letter
Black Diamond Therapeutics, Servier Sign Global Licensing Deal for BDTX-4933 to Treat Solid Tumors - Marketscreener.com
Servier and Black Diamond enter oncology licensing deal - Investing.com India
Black Diamond rises on licensing deal for tumor treatment - TradingView
Black Diamond stock soars on licensing deal By Investing.com - Investing.com Australia
Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy - Marketscreener.com
Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire
HC Wainwright Issues Positive Forecast for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Black Diamond Therapeutics Reports 2024 Financial Results - MSN
Black Diamond Therapeutics: In Decline, But Why? (NASDAQ:BDTX) - Seeking Alpha
Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $1.76 amid market challenges - Investing.com Australia
BDTX stock touches 52-week low at $1.76 amid market challenges By Investing.com - Investing.com South Africa
Black Diamond Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Brokers Issue Forecasts for BDTX Q1 Earnings - Defense World
Stifel Nicolaus Lowers Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $15.00 - Defense World
Black Diamond Therapeutics Inc (BDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):